Literature DB >> 12560432

Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems.

Erica Villa1, Alessandra Colantoni, Calogero Cammà, Antonella Grottola, Paola Buttafoco, Roberta Gelmini, Ilva Ferretti, Federico Manenti.   

Abstract

PURPOSE: Several scoring systems to evaluate patients with hepatocellular carcinoma (HCC) exist. A good scoring system should provide information on prognosis and guide therapeutic decisions. The presence of variant liver estrogen receptor (ER) transcripts in the tumor has been shown to be the strongest negative predictor of survival in HCC. The aim of this study was to compare the predictive value of the commonly applied clinical scoring systems for survival of patients with HCC with that of the evaluation of ER in patients with HCC (molecular scoring system).
MATERIALS AND METHODS: HCC was staged according to the Okuda classification, Barcelona Clinic Liver Cancer classification, Italian classification system (CLIP), French classification, and ER status in 96 patients. Analysis of survival was performed according to the Kaplan-Maier test and was made for each classification system and ER. A comparison between classifications was made by univariate and multivariate analysis.
RESULTS: Among the clinical classification systems, only the CLIP was able to identify patient populations with good, intermediate, and poor prognosis. On multivariate analysis, ER classification was shown to be the best predictive classification for survival of patients with HCC (P <.0001). This difference was the result of a better allocation of patients with ominous prognosis (variant ER) having nevertheless good clinical score.
CONCLUSION: The evaluation of the presence of wild-type or variant ER transcripts in the tumor is the best predictor of survival in patients with HCC. Its accuracy in discriminating patients with good or unfavorable prognosis is significantly greater than that of the commonly used scoring systems for the staging of HCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12560432     DOI: 10.1200/JCO.2003.11.051

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  22 in total

1.  Opposing action of estrogen receptors alpha and beta on tumor necrosis factor-alpha gene expression and caspase-8-mediated apoptotic effects in HA22T cells.

Authors:  Erh-Jung Huang; Cheng-Chung Wu; Shin-Da Lee; Juen-Hau Chen; Jer-Yuh Liu; Jiunn-Liang Ko; James A Lin; Min-Chi Lu; Li-Mien Chen; Chih-Yang Huang; Wei-Wen Kuo
Journal:  Mol Cell Biochem       Date:  2006-04-22       Impact factor: 3.396

2.  Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre.

Authors:  A Grieco; M Pompili; G Caminiti; L Miele; M Covino; B Alfei; G L Rapaccini; G Gasbarrini
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 3.  Staging systems of hepatocellular carcinoma: a review of literature.

Authors:  Marcello Maida; Emanuele Orlando; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 4.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Interplay of estrogen receptors and FOXA factors in the liver cancer.

Authors:  Yongbing Zhao; Zhaoyu Li
Journal:  Mol Cell Endocrinol       Date:  2015-02-04       Impact factor: 4.102

Review 6.  Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology.

Authors:  Jan Hansmann; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

7.  Are surgical indications of Barcelona Clinic Liver Cancer staging classification justified?

Authors:  Shuang Wei; Xiaoyi Hao; Daqian Zhan; Min Xiong; Kaiyan Li; Xiaoping Chen; Zhiyong Huang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

8.  Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma.

Authors:  Yin-Nong Zhao; Yong-Quan Zhang; Jia-Zhou Ye; Xing Liu; Hong-Zhi Yang; Feng-Yun Cong; Bang-De Xiang; Fei-Xiang Wu; Liang Ma; Le-Qun Li; Hai-Hong Ye
Journal:  Exp Ther Med       Date:  2016-10-17       Impact factor: 2.447

9.  Staging systems in hepatocellular carcinoma.

Authors:  Fernando Pons; Maria Varela; Josep M Llovet
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

10.  Prognostic scores for hepatocellular carcinoma: none is the winner.

Authors:  Calogero Cammà; Giuseppe Cabibbo
Journal:  Liver Int       Date:  2009-04       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.